下尿路症状相关生物标志物:系统综述与通路分析
该系统综述检索了截至2018年2月13日的PubMed、EMBASE和Web of Science数据库,纳入125项良性泌尿人群研究,评估生物标志物与下尿路症状的关联或预测能力。大多数研究(93.6%)为单时间点横断面研究,目前尚无单个生物标志物被验证为下尿路症状的诊断工具。通路分析发现,与对照相比,膀胱过度活动症富集多种免疫应答通路,女性压力性尿失禁富集细胞迁移/细胞骨架重塑通路。
要点
- 现有生物标志物文献的主要缺陷包括实验室数据可重复性差、下尿路症状患者分类不明确及缺乏对临床协变量的调整。
- 大多数研究(93.6%)在单一时间点评估生物标志物,本质上为横断面研究。
- 通路分析识别出膀胱过度活动症中富集的免疫应答通路及女性压力性尿失禁中富集的细胞迁移/细胞骨架重塑通路。
核心结论
- 现有生物标志物文献存在重大缺陷,包括实验室数据可重复性差、下尿路症状患者分类不明确及缺乏对临床协变量的调整。
- 尽管存在这些局限性,仍识别出多个推定通路,其中的生物标志物组合需要进一步研究。
研究设计与样本
- 系统综述,检索PubMed、EMBASE和Web of Science数据库自建库至2018年2月13日的文献。
- 纳入标准为英文文献、在无神经系统疾病或间质性膀胱炎/膀胱疼痛综合征的良性泌尿人群中开展、评估生物标志物与特定下尿路症状或泌尿系统疾病的关联或预测能力。
- 共鉴定6150条引文,其中125项研究符合纳入标准。
- 进行了生物信息学通路分析,以确定与症状相关的个体生物标志物是否存在于统一通路中。
主要发现
- 大多数研究(93.6%)在单一时间点评估生物标志物,本质上为横断面研究。
- 很少有研究对潜在混杂临床变量进行调整,或在个体中随时间评估生物标志物。
- 目前尚无单个生物标志物被验证为下尿路症状的诊断工具。
- 与对照相比,通路分析识别出膀胱过度活动症中富集的多种免疫应答通路。
- 与对照相比,通路分析识别出女性压力性尿失禁中富集的细胞迁移/细胞骨架重塑通路。
临床怎么用
- 原文未据此给出推荐。
局限性
- 现有生物标志物文献的主要缺陷包括实验室数据可重复性差。
- 下尿路症状患者分类不明确。
- 缺乏对临床协变量的调整。
- 大多数研究(93.6%)在单一时间点评估生物标志物,本质上为横断面研究。
- 很少有研究对潜在混杂临床变量进行调整,或在个体中随时间评估生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lower urinary tract symptoms are prevalent and burdensome, yet methods to enhance diagnosis and appropriately guide therapies are lacking. We systematically reviewed the literature for human studies of biomarkers associated with lower urinary tract symptoms. MATERIALS AND METHODS: PubMed®, EMBASE® and Web of Science® were searched from inception to February 13, 2018. Articles were included if they were in English, performed in benign urological populations without neurological disorders or interstitial cystitis/bladder pain syndrome, and assessed a biomarker's association with or ability to predict specific lower urinary tract symptoms or urological conditions. Bioinformatic pathway analyses were conducted to determine whether individual biomarkers associated with symptoms are present in unifying pathways. RESULTS: Of 6,150 citations identified 125 met the inclusion criteria. Most studies (93.6%) assessed biomarkers at 1 time point and were cross-sectional in nature. Few studies adjusted for potentially confounding clinical variables or assessed biomarkers in an individual over time. No individual biomarkers are currently validated as diagnostic tools for lower urinary tract symptoms. Compared to controls, pathway analyses identified multiple immune response pathways that were enriched in overactive bladder syndrome and cell migration/cytoskeleton remodeling pathways that were enriched in female stress incontinence. CONCLUSIONS: Major deficiencies in the existing biomarker literature include poor reproducibility of laboratory data, unclear classification of patients with lower urinary tract symptoms and lack of adjustment for clinical covariates. Despite these limitations we identified multiple putative pathways in which panels of biological markers need further research.
引用
- Siddiqui NY, Helfand BT, Andreev VP, et al. Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. J Urol. 2019. PMID: 30925127. doi:10.1097/JU.0000000000000257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。